Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

This study is currently recruiting participants.

Verified May 2013 by Ohio State University Comprehensive Cancer Center

Study NCT00989586 Information provided by Ohio State University Comprehensive Cancer Center

First Received on October 2, 2009. Last Updated on May 6, 2013 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Lymphoma

Additional conditions recognized in this trial

More general conditions related to this trial

Interventions listed in this trial

Additional drug interventions recognized in this trial

Antibodies
Antibodies, Monoclonal
Immunoglobulins
Rituximab

More general drug interventions related to this trial

Sponsors listed in this trial

Beth Christian
Immunomedics, Inc.